biostudies-literatureVilleneuve SCanada First Research Excellence FundFonds de recherche du Québec - SantéEU Joint Programme Neurodegenerative Disease ResearchVetenskapsrådetNIA NIH HHSFondation de la Famille LemaireAlzheimer's AssociationAlzheimer Society of CanadaNational Institute on AgingCanadian Institutes of Health ResearchCIHRFondation Brain CanadaAlzheimer SocietyFondation Jean-Louis LévesqueCanada Foundation for InnovationAlzheimer's Associatione70653https://www.ebi.ac.uk/biostudies/studies/S-EPMC12477627biostudies-literatureUnknown21(10)The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle meaAlzheimer's & dementia : the journal of the Alzheimer's AssociationThe PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond.PMC12477627NIG‐17‐083R01AG068563-04S1PJT-178210SG-23-1038904QC3R01AG068563‐04S1PJT-438655PJT-451830PJT-410106PJT‐463677PJT‐410106JPND2019-466-236R01AG068563PJT‐451830PJT‐438655PJT‐178210PJT-165921PJT-367122PJT-1532872022-00732SG‐23‐1038904QCPJT‐1659212017‐00915AARG-22-927100NIG-17-08AARG‐22‐927100PJT‐367122PJT‐1532872017-00915PJT-4636772022‐00732Bocti CBreitner JCSEdde MSpreng RNOurry VTardif CLChakravarty MMPoirier JZetterberg HSanami SDavatzikos CVilleneuve SLaforce RPREVENT‐AD Research GroupStrikwerda-Brown CMontembeault MQiu TFajardo Valdez ARajah NRaoult JMDadar MRemz JBaillet SBaril AABellec LRosa-Neto PTremblay-Mercier JGauthier CJPichet Binette APastor-Bernier AGeddes MRSoucy JPJavanray MCollins DLMohammediyan BWearn AEvans ACMetz AVachon-Presseau EDucharme SDescoteaux MGallego-Rudolf JYakoub YGonneaud JBlennow KfalseThe PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond.The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle mea2025-01-01T00:00:00Z2025 Oct2026-06-04T05:09:32.851Z2026-05-05T03:12:47.032ZS-EPMC124776274102041210.1002/alz.70653